CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?

CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. By selectively depleting CD19-positive B-cells, this therapy brings a new approach in resetting immun...

Full description

Saved in:
Bibliographic Details
Main Authors: Marie José Kersten, Maria Theresa Kuipers
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/12/1/e001157.full
Tags: Add Tag
No Tags, Be the first to tag this record!